Salute e Benessere

Ultimovacs Receives EMA Orphan Drug Designation for UV1 Cancer Vaccine for the…

The Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) was granted based on results from the randomized Phase II clinical trial NIPU, which showed improved overall survival with UV1 in combination with ipilimumab and nivolumab in patients with malignant pleural mesothelioma UV1 has also received U.S. Food and Drug Administration ODD for UV1 in the treatment of patients with mesothelioma and malignant stage IIB-stage IV melanoma Oslo, February 19, 2024:...
Nasdaq GlobeNewswire
19/02/2024

CARBIOS rallies players to promote textile circularity sector in the presence of…

CARBIOS rallies players to promote textile circularity sector in the presence of M. Bruno Le Maire, Minister of Economy, Finance and Industrial and Digital SovereigntyClermont-Ferrand, France, 19 February 2024 (06.45am CET) CARBIOS(Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, was honored to welcome Mr. Bruno Le Maire, Minister of the Economy, Finance, Industrial and...
Nasdaq GlobeNewswire
19/02/2024

Waycen and MegaMind Sign AI Endoscopy supply Agreement to Medical market in the…

MegaMind, IT Solution a specialized company located in Saudi Arabia, owns 13 group hospitals within the Middle East region. Additionally, it is actively engaged in digital projects with over 40 government and private healthcare institutions in Saudi Arabia. MegaMind plays a significant role in leading digital innovation in Middle Eastern healthcare institutions through projects such as establishing 15 to 25 data centers for Middle Eastern hospitals annually and collaborating with the government…
PR Newswire
19/02/2024

SIBIONICS Announced to Exhibit at the 17th International Conference on Advanced…

Having received CE MDR certification in October 2023, SIBIONICS CGM entered the European market in November. With strong product capabilities and positive user feedback, SIBIONICS quickly expanded global partnerships. In 2024, driven by the company's commitment to customer-centric innovation, SIBIONICS is dedicated to engaging with users for a co-developed CGM solution that precisely aligns with their needs. The commitment extends beyond Type 1 diabetes, focusing on Type 2 diabetes, prediabetes…
PR Newswire
19/02/2024

India Ethanol Market Size to Surpass Around US$ 6.83 Billion 2030, Recording a…

The India Ethanol Market is expected to witness high growth due to the increasing demand for biofuels. Ethanol is a renewable source of energy and is primarily used as a feedstock for biodiesel production. The growing concern for energy security and environmental sustainability is driving the demand for biofuels in India. Additionally, the government initiatives and policies promoting the use of biofuels, such as the National Policy on Biofuels, are further fueling the growth of the ethanol…
PR Newswire
16/02/2024

Groupe Casino: Proceedings for recognition of financial restructuring in the…

Proceedings for recognition of financial restructuring in the United States (Chapter 15) Paris, 16 February 2024Casino announces that on 15 February 2024 it filed petitions before the Bankruptcy Court of the Southern District of New York for the opening of Chapter 15 proceedings under the U.S. Bankruptcy Code.The purpose of these proceedings is to obtain recognition in the United States of (i) the accelerated safeguard proceedings at the level of Casino and six of its subsidiaries 1...
Nasdaq GlobeNewswire
16/02/2024

FDA approves Xolair as first and only medicine for children and adults with one…

Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew without an allergic reaction, compared to placebo More than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once 1,2 Detailed OUtMATCH results will be featured in a...
Nasdaq GlobeNewswire
16/02/2024

Real World Evidence Solutions Market Worth $4.5 Billion | MarketsandMarkets™.

Browse in-depth TOC on "Real World Evidence Solutions Market" Browse in-depth TOC on "Real World Evidence Solutions Market" 190 - Tables 60 - Figures 265 - Pages Real World Evidence Solutions Market Scope: Services accounted for the larger share of the Real-World Evidence Solution market in 2023. On the basis component, the Real-World Evidence Solution market is segmented into services and data sets. The services accounted for the larger share of this segment in...
PR Newswire
16/02/2024

Vistin Pharma ASA: Key information relating to the proposed cash dividend

The Board of Directors of Vistin Pharma ASA plans to propose to distribute a cash dividend of total NOK 1.00 per share, to be paid partly in June and November, for the accounting year of 2023. The formal decision regarding the dividend will be made on the company's Annual General Meeting, which will be held on 23 May 2024. Dividend amount (per share): NOK 0.50Declared currency: NOKLast day including right: 4 June 2024Ex-date: 5 June 2024Record date: 6 June 2024Payment date (on or...
Nasdaq GlobeNewswire
16/02/2024

IFPA Releases an Innovative Psoriatic Care Roadmap and Action Playbook

The IFPA Forum Roadmap for Asia is a strategic guide featuring advocacy demands and practical strategies that aim to elevate psoriatic care across the continent. Patient associations are encouraged to raise awareness about the burden of psoriatic disease and advocate for its higher prioritization within national and regional policies. By following this roadmap, stakeholders hope to pave the way for enhanced health and well-being for those living with psoriatic disease. The IFPA Forum Roadmap...
PR Newswire
16/02/2024

4 WAYS THE BEEM BY START UP MUDO LABS ON KICKSTARTER WILL REVOLUTIONIZE THE WAY…

Those numbers are worrying and while the methods to manage our moods are endless (take your pick from exercise, meditation, yoga) few actually allow us to hold space for our emotions while on the go. Those numbers are worrying and while the methods to manage our moods are endless (take your pick from exercise, meditation, yoga) few actually allow us to hold space for our emotions while on the go. Enter The Beem, an innovative device bySingapore -based startup Mudo Labs which lets you...
PR Newswire
16/02/2024

Enzymatica's rights issue is secured to 100 percent

In connection with the rights Issue, Enzymatica has received subscription commitments from the Company's three largest shareholders, the Chairman of the Board, two members of the Board of Directors and the Company's CEO amounting to SEK 14.0 million, corresponding to approximately 51.1 percent of the rights issue. In addition, the Company has entered into underwriting agreements amounting to SEK 13.4 million, corresponding to approximately 48.9 percent of the rights issue, with the Company's…
PR Newswire
16/02/2024

Year-end report 2023: Scientific and regulatory progress generating…

• Earnings per share, basic and diluted, were SEK -0.09 (-0.14). • Earnings per share, basic and diluted, were SEK -0.09 (-0.14). • Cash flow from operating activities totaled SEK -2.6 (-27.7) million. • Earnings per share, basic and diluted, were SEK -0.30 (-0.44). • Cash flow from operating activities for the period totaled SEK -40.3 (-65.4) million. • Net cash totaled SEK -17.7 (28.4) million at year-end. "It is with mixed...
PR Newswire
16/02/2024

New study shows Nevisense evaluates skin barrier function with less sensitivity…

The study was performed on healthy adults between 22 and 65 years of age and aimed at determining factors that influence the measurement results of both EIS and TEWL. The top-line results of the study indicated that: The study was performed on healthy adults between 22 and 65 years of age and aimed at determining factors that influence the measurement results of both EIS and TEWL. The top-line results of the study indicated that: The authors concluded that EIS...
PR Newswire
16/02/2024

Implantica publishes Year-end Report, January - December 2023 (Q4)

Significant events after the end of the period Significant events after the end of the period Fourth quarter financial summary Full year financial summary Telephone conference Implantica will hold a teleconference on16 February 2024at 15:00 (CET) withPeter Forsell(CEO), Andreas Öhrnberg (CFO), andNicole Pehrsson(Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference: Webcast: ...
PR Newswire
16/02/2024

Enzymatica's Board of Directors decides on a new rights issue of SEK 27.4…

Background and reasons Background and reasons Enzymatica AB develops and sells health products to treat diseases and symptoms in the upper respiratory tract. The products are based on a patented enzyme formulation, Penzyme, that includes marine enzymes with unique properties. The company's main product based on the Penzyme platform is the medical device product ColdZyme®, a mouth spray for colds. The product has been launched in more than 30 markets on four continents. In 2023,...
PR Newswire
16/02/2024

Vistin Pharma ASA: Fourth quarter and preliminary 2023 financial results

thof February 2024Vistin Pharma ASA (Vistin Pharma, OSE: VISTN) today announces the financial results for the fourth quarter of 2023.Vistin delivers another strong quarter with a 12% revenue growth compared to same quarter last year. Revenue in the fourth quarter ended at MNOK 111 compared to MNOK 99 in Q4 2022. Sales volume in the quarter was up by 11%. Revenue for FY 2023 ended at MNOK 438 compared to MNOK 305 in 2022, a 44% increase.Fourth quarter EBITDA ended at MNOK 25 (Q4'22...
Nasdaq GlobeNewswire
16/02/2024

Bioretec Ltd's financial statements bulletin 2023: Another successful year in…

July-December 2023 in brief July- December 2023in brief January- December 2023in brief Key events in 2023 This financial statements bulletin is unaudited. The full-year 2022 figures are audited. Key figures Timo Lehtonen, CEO of Bioretec Ltd: "In 2023, Bioretec achieved a historic milestone by becoming the first player to receive an FDA market authorization in the U.S. for a biodegradable metal product with our...
PR Newswire
16/02/2024

Press Release: Japan first in the world to approve Dupixent® for chronic…

Japan first in the world to approve Dupixent ®for chronic spontaneous urticaria (CSU) Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placeboCSU is the fifth approved indication for Dupixent in Japan and the sixth indication for Dupixent globallyParis and Tarrytown, N.Y. February 16, 2024.The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for...
Nasdaq GlobeNewswire
16/02/2024

Kanazawa University research: Chromatin Accessibility: A new avenue for gene…

Now, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, led by Yusuke Miyanari, have used advanced genetic screening methods to unravel chromatin accessibility and its pathways. Now, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, led by Yusuke Miyanari, have used advanced genetic screening methods to unravel chromatin accessibility and its pathways. For the investigation the team used a combination of two technologies—CRISPR...
PR Newswire
16/02/2024

Inventiva reports preliminary 2023 fiscal year financial Information¹ and…

Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022Cash and cash equivalents at €26.9 million, short-term deposits at € 0.01 million 2, and long-term deposit at €9.0 million 3as of December 31, 2023, compared to €86.7 million, €1.0 million, and €0.7 million respectively, as of December 31, 2022 Receipt on January 18, 2024 of the second tranche of €25 million under the EIB loan agreement 4 Estimated cash runway until the beginning of the third...
Nasdaq GlobeNewswire
15/02/2024

Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on…

Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024Mont-Saint-Guibert, Belgium – February 15, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the fourth quarter and financial year 2023...
Nasdaq GlobeNewswire
15/02/2024

Galapagos presents at EBMT-EHA annual meeting 2024

Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical data from ongoing Phase 1/2 CD19 CAR-T studies Mechelen, Belgium; 15 February 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) to present new preliminary translational data and previously disclosed data at the European Society for Blood and Marrow Transplantation (EBMT)-European Hematology Association (EHA) 6 thEuropean CAR T-cell meeting taking place from...
Nasdaq GlobeNewswire
15/02/2024

Mithra sells shares in Mayne Pharma

Mithra sells shares in Mayne PharmaMithra sold all 4,221,815 shares it held in Mayne Pharma for EUR ~12.8 millionAs the Mayne Pharma shares were pledged to the secured lenders of Mithra, the cash proceeds will be held in escrow by appointed security agents of lendersLiege, Belgium, 15 February 2024 – 08:30 CET– Mithra (Euronext Brussels: MITRA), a company dedicated to women's health, today announces the sale of all 4,221,815 shares it held in Mayne Pharma Group Limited...
Nasdaq GlobeNewswire
15/02/2024
Altri  Comunicati